The company says it has finalized the contents of the product line and the packaging and is now looking to distribute it through physicians worldwide during the first quarter of 2009.
The range includes a serum, a day cream, a night cream, a cleanser and an exfoliator, that have all been developed using Proteonomix expertise in stem-cell research to help target areas of the skin prone to signs of aging.
Launch includes two website
In conjunction with the new launch, the company has developed two websites - one which concentrates on promoting the product range, and one aimed at physicians interested in distributing the product line as part of their practices.
The company, which was formally known as National Stem Cell Holding, first announced that it was launching the new cosmeceutical line at the July Anti-Aging Conference, held in Washington, DC.
However this is the first concrete move towards getting the product out to the customer base and company CEO Michael Cohen says that executives are currently in negotiations with a number of foreign distributors for the right to sell the product line.
Incorporating embryonic cells
The five products in the cosmeceutical line incorporates tropelastin secreted from human embryonic stem cells.
Proteonomix claims the ingredient enhances the natural formation of collagen and binds with existing protein chains in the skin to make it appear smoother and firmer.
Tropelastin already affects skin appearance naturally in pregnant women.
Proteonomix CEO Michael Cohen told CosmeticsDesign.com that the inspiration for the products came from the natural glow of women post-conception that is caused by the release of the chemical from embryonic stem cells.
Stem cell is the future
Scientists at the recent HBA show, held in New York last month, have pointed to the fact that stem cell technology could mark a new era for anti-aging treatments.
In a show conference session led by Eric Perrier from LVMH, scientists discussed the potential new research into skin stem cells will have on the cosmetics market.
During his presentation Perrier underlined his belief that this, and other new areas of research, emphasize how skin is no longer ‘hope in a jar’ but instead ‘efficacy in a jar’.